The ecto-ATPDase CD39 is involved in the acquisition of the immunoregulatory phenotype by M-CSF-macrophages and ovarian cancer tumor-associated macrophages: Regulatory role of IL-27

ABSTRACT

Tumor-associated macrophages (TAM) are immunosuppressive cells that can massively accumulate in the tumor microenvironment. In patients with ovarian cancer, their density is correlated with poor prognosis. Targeting mediators that control the generation or the differentiation of immunoregulatory macrophages represents a therapeutic challenge to overcome tumor-associated immunosuppression. The ectonucleotidase CD39 hydrolyzes ATP into extracellular adenosine that exhibits potent immunosuppressive properties when signaling through the A2A adenosine receptor. We report here that CD14⁺ CD163⁺ TAM isolated from ovarian cancer patients and macrophages generated in vitro with M-CSF, express high levels of the membrane ectonucleotidase CD39 compared to classically activated macrophages. The CD39 inhibitor POM-1 and adenosine deaminase (ADA) diminished some of the immunosuppressive functions of CD14^high CD163^high CD39^high macrophages, such as IL-10 secretion. We identified the cytokine IL-27, secreted by tumor-infiltrating neutrophils, located close to infiltrating CD163⁺ macrophages, as a major rheostat of CD39 expression and consequently, on the acquisition of immunoregulatory properties by macrophages. Accordingly, the depletion of IL-27 downregulated CD39 and PD-L1 expression as well as IL-10 secretion by M-CSF-macrophages. Collectively, these data suggest that CD39, drived by IL-27 and CD115 ligands in ovarian cancer, maintains the immunosuppressive phenotype of TAM. This work brings new information on the acquisition of immunosuppressive properties by tumor-infiltrating macrophages.

Introduction

Macrophages are involved in numerous functions, ranging from tissue homeostasis to microbe eradication. Accordingly, they can exhibit different states of polarization,¹ with M1 and M2 representing two extreme states of a continuum spectrum of activation. M1-polarized macrophages, also named “classically activated macrophages,” are characterized by an IL-12^high IL-10^low phenotype. They play a protective role against microbes and tumors via the production of inflammatory cytokines. M2-polarized macrophages, referred to as “alternatively activated macrophages,” exhibit immunoregulatory properties, and are characterized by an IL-10^high IL-12^low phenotype and the ability to suppress Th1 immunity. M2-type macrophages are involved in the resolution of inflammation and the protection against some parasites. They also promote angiogenesis, tissue remodeling and wound healing.^2,3

Macrophages are plastic cells. Their phenotype and functions can be modulated, depending on their microenvironment. As an example, type I and type II IFNs can revert M2-type macrophages into immunostimulatory cells.⁴ To the same extent, GM-CSF prevents the differentiation of human monocytes into immunosuppressive macrophages.⁵

At the tumor site, the accumulation of immunosuppressive cells abrogates effector cell functions and contributes to maintain tumor-immune tolerance.⁶ In various solid tumors, such as breast and ovarian cancers, tumor-associated macrophages (TAM) accumulate more than any other immune cell type, and their density is correlated with poor prognosis.⁷ TAM derive from circulating monocytes recruited locally by CCL2, M-CSF and/or VEGF.⁸ TAM exhibit an immunoregulatory phenotype and suppress antitumor immune responses by altering the cytotoxic properties of CTLs and by promoting apoptosis or inhibiting the proliferation of effector T cells. Via its ability to switch the differentiation of monocytes from DCs into macrophages, to favor the expression of inhibitory molecules on myeloid cells and to prevent T cell priming, IL-10 appears as the prominent immunoregulatory mediator expressed by TAM. Moreover, TAM favor the local recruitment of Treg cells by secreting CCL22.⁹ We have previously reported that the CD115 ligands M-CSF and IL-34, drive monocytes into IL-10^high IL-12^low immunoregulatory macrophages which are similar to ovarian cancer TAM.^5,10,11 They represent a robust model to decipher in vitro the biology of immunoregulatory macrophages.

Accumulating data have underlined the impact of the local tumor-associated metabolism in regulating the recruitment and/or functional polarization of immune cells, among which ATP and its metabolites have emerged as potent regulators of immune cells.^12,13 However, and to the best of our knowledge, the role of tumor-associated ATP metabolites on functional macrophage polarization has not been addressed in detail.

In an inflammatory context, extracellular ATP is considered as a potent danger signal that activates immune cells via P2 receptors.^14-16 It was previously described that, under activation or stress, numerous cell types and particularly monocytes, release ATP.^16,17 ATP is important for immune cell response, it attracts antigen-presenting cells and potentiates the initiation of protective antitumor immune responses.^18,19 Even though inflammation is important for pathogens and tumor cells eradication, a chronic inflammation could be detrimental to the host. Consequently, ATP has to be removed from the extracellular milieu to avoid unabated inflammation. Landmark studies of Ohta and Sitkovsky highlighted the importance of adenosine in immunoregulation.²⁰ ATP could be rapidly shifted into an immunosuppressive mediator upon catabolism into adenosine, a well-known potent inhibitor of immune cells.^20-29 This observation led to analyze the cellular-mediated ATP catabolism. ATP is essentially hydrolyzed by the membrane-bound nucleotidase CD39 (NTPDase1, nucleoside triphosphate diphosphohydrolase 1) into ADP and AMP, the latter being dephosphorylated by the ecto-5′nucleotidase CD73 into adenosine.^29-31 Ohta, Sitkovsky and others showed that, among the different adenosine receptors (A1, A2A, A2B and A3),²⁶ the adenosine receptor 2A has a major role in the attenuation of inflammation and tissue damage.^20,21,32-35 These studies evidenced the CD39-CD73-adenosine receptor axis blockade as a promising therapeutic target.^31,36-42

In line with these studies and with the objective to better understand the mechanism involved in the acquisition by TAM of an immunoregulatory phenotype, this study aimed at evaluating the impact of ATP and ATP metabolites on TAM functions.

In tumors, all these partners are present: (i) ATP is mainly released by dying cells and infiltrated immune cells,^12,13 (ii) CD39 and CD73 are expressed by numerous primary tumor cells ^43,44 and by some infiltrating immunosuppressive cells ^45-48 and (iii) adenosine receptor 2A is expressed by immune-infiltrating cells.⁴¹ Furthermore, an accumulation of extracellular adenosine in tumor microenvironment and the subsequent purinergic signaling are involved in the regulation of immune cell functions.^20,31,36,40

In this context, we hypothesized that the CD39-CD73-adenosine receptor axis plays a strategic role in the acquisition of immunoregulatory properties by tumor-infiltrating macrophages. The objective of this study was to investigate the role of CD39 in the polarization of human macrophages generated using CD115 ligands and of TAM isolated from ovarian cancer patients.

Results

M-CSF-macrophages and ovarian cancer TAM express higher levels of CD39 than GM-CSF-macrophages

We analyzed, by flow cytometry, the expression of CD39 by M-CSF-macrophages and GM-CSF-macrophages, used as prototypes of M2-polarized and M1-polarized macrophages, respectively. Results showed that, at the end of the differentiation process (day 7), the expression of CD39 was higher on M-CSF-macrophages, compared to GM-CSF-macrophages (RFI = 5.8 ± 0.82 and RFI = 2.96 ± 0.37, respectively; mean ± SEM, n = 11) (Fig. 1A). Interestingly, the expression of CD39 was increased during the differentiation process on M-CSF-macrophages (Fig. 1B). On the contrary, CD39 expression remained stable on GM-CSF-macrophages during the 7-d differentiation process and was only slightly increased compared to freshly isolated monocytes (Fig. 1B). We previously reported that M-CSF-macrophages are similar to TAM isolated from ovarian cancer patients.¹¹ M-CSF-macrophages and TAM are CD14^high CD163^high that produce high amounts of IL-10, but not IL-12, upon stimulation with LPS (Fig. 2C and data not shown).¹¹ We observed that the levels of CD39 on ovarian cancer TAM isolated from patients are similar to the ones of M-CSF-macrophages (RFI = 6.28 compared to 5.8, respectively; mean, n = 5 and n = 11, respectively) (Fig. 1A). IHC confirmed, in ovarian cancer tissues, that CD14+ macrophages express CD39 (Fig. S1).

Figure 1.

CD39 is more expressed in M-CSF-Mφ and TAM from ovarian cancer patients compared to GM-CSF-Mφ (A) The expression of CD39 was analyzed by flow cytometry on GM-CSF-Mφ, M-CSF-Mφ and TAM isolated from patients. Results are expressed in relative fluorescent intensity (RFI values are the ratio of antibody/isotype control antibody) (mean ± SEM, n = 11 for M-CSF-Mφ, GM-CSF-Mφ and n = 5 for TAM), *p < 0 .05 compared to GM-CSF-Mφ (B) M-CSF-Mφ polarization results in the acquisition of CD39 expression whereas GM-CSF-Mφ polarization results in its maintenance. CD39 expression was analyzed by flow cytometry. Results are expressed in RFI values, as mean ± SEM (n = 4 for monocytes, n = 11 for GM-CSF-Mφ and n = 11 for M-CSF-Mφ). (C) HPLC analysis of Etheno-ATP (ATP), -ADP (ADP), -AMP (AMP) and -adenosine (Ado) are expressed in percentage compared to the initial dose of ATP (200 µM = 100%) during 20 min. in GM-CSF-Mφ and M-CSF-Mφ (mean of two representative donors). In certain conditions, CD39 inhibitor (POM-1) was used at 10 µM.

Figure 2.

Secretion profile after CD39 blockade with POM-1 in GM-CSF-Mφ, M-CSF-Mφ and TAM isolated from patients (A) M-CSF-Mφ and TAM were stimulated with LPS (200 ng/mL) with or without POM-1 (10 µM), ATP (1 mM) for 6 h. M-CSF-Mφ and TAM isolated from patients were stimulated with LPS (200 ng/mL) with or without ADA (2.5 UI/mL) for 24 h. (B) GM-CSF-Mφ were stimulated with LPS (200 ng/mL) with or without POM-1 (10 µM) for 6 h. (A and B) IL-1β secretion in supernatant was analyzed by ELISA (pg/mL). Results are expressed in pg/mL (mean ± SEM, M-CSF-Mφ: n = 4 for POM-1 and ATP experiments, n = 9 for ADA experiment; TAM: n = 3 for POM-1 and ATP; GM-CSF-Mφ: n = 5, *p <0.05 compared to LPS alone). (C) M-CSF-Mφ and TAM isolated from patients were stimulated with LPS (200 ng/mL) with or without POM-1 (10 µM) or ADA (2.5 UI/mL) for 24 h. The secretion of IL-10 was analyzed by ELISA. Results are expressed in ng/mL as mean ± SEM (M-CSF-Mφ: n = 7 for POM-1 experiment and n = 8 for ADA experiment; TAM: n = 4 for POM-1 experiment and n = 5 for ADA experiment). (D) M-CSF-Mφ were stimulated with LPS (200 ng/mL) with or without POM-1 (10 µM) during 24 h. Expression of PD-L1 by M-CCSF-Mφ was analyzed by flow cytometry. Results are expressed in mean ± SEM of percentage of RFI compared to LPS-stimulated M-CSF-Mφ as 100% (n = 4).

GM-CSF-macrophages and M-CSF-macrophages express functional CD39

In order to evaluate the functionality of CD39, we quantified the degradation of exogenous etheno-ATP into ADP, AMP and adenosine (ADO) by GM-CSF-macrophages and M-CSF-macrophages. After 20 min., more than 80% of ATP is hydrolyzed by both macrophages subsets (Fig. 1C). Furthermore, M-CSF-macrophages hydrolyzed extracellular etheno-ATP more efficiently than GM-CSF-macrophages (3.9 µM/min vs. 2.9 µM/min, respectively; mean of two representative experiments) while producing more AMP compared to GM-CSF-macrophages from 0 min to 20 min (61.2% vs. 47.7%, respectively). These results confirmed that a high level of CD39 expression by M-CSF-macrophages was associated to a high ATPase activity compared to GM-CSF macrophages. Finally, the addition of the CD39 inhibitor POM-1 prevented extracellular ATP and ADP from hydrolysis in both M-CSF- and GM-CSF-macrophages (Fig. 1C and Fig. S2). This result confirms the role of CD39 in the metabolism of extracellular ATP in by M-CSF-macrophages.

Previous study has reported that the secretion of IL-1β is correlated to the concentration of extracellular ATP,⁴⁹ therefore quantification of mature IL-1β in culture supernatants allowed us to monitor extracellular ATP release by macrophages. Therefore, we evaluated the impact of CD39 inhibition on ATP dependent IL-1β secretion by M-CSF-macrophages (Fig. 2A, left panel). As previously reported,⁵⁰ LPS triggered IL-1β secretion by GM-CSF-macrophages (Fig. 2B and Fig. S3A) but induced low levels of IL-1β by M-CSF-macrophages (Fig. 2A, left panel). However, no IL-1β was produced by non-stimulated macrophages (data not shown). Interestingly, IL-1β secretion was increased in M-CSF-macrophages upon stimulation with LPS in the presence of POM-1 (6.59-fold increase; mean, n = 5) (Fig. 2A, left panel). A moderated but reproducible increase of IL-1β secretion was observed using TAM isolated from ovarian cancer patients stimulated in the presence of POM-1 (3.65-fold increase; mean, n = 3) (Fig. 2A, right panel). By contrast, POM-1 only marginally modulated IL-1β secretion by GM-CSF-macrophages (1.3-fold increase; mean, n = 5) (Fig. 2B and Fig. S3A). These results suggest an autocrine role of ATP and of its metabolites in regulation of M-CSF-macrophages properties.

CD39 is involved in the acquisition of the immunoregulatory phenotype by M-CSF-macrophages and ovarian cancer TAM

We therefore evaluated whether CD39 is involved in the acquisition of an immunoregulatory phenotype by M-CSF-macrophages and TAM isolated from ovarian cancer patients. Interestingly, inhibiting CD39 with POM-1 significantly decreased the production of IL-10 by M-CSF-macrophages in response to LPS (7.18 ± 1.22 ng/mL and 1.99 ± 1.04 ng/mL without and with POM-1, respectively; mean ± SEM, n = 7; p value = 0.011) (Fig. 2C left panel). A similar but not statistically significant effect was observed on ovarian cancer TAM (6.14 ± 2.22 ng/mL compared to 1.36 ± 0.88 ng/mL with and without POM-1, respectively; mean ± SEM, n = 4) (Fig. 2C, right panel) and GM-CSF-macrophages (4.66 ± 0.93 ng/mL compared to 0.68 ± 0.38 ng/mL; mean ± SEM, n = 5; p value = 0.03) (Fig. S3B). This decrease of IL-10 production was associated with a decrease of IL-10 mRNA expression in all macrophage subsets (Fig. S3C). In contrast, the expression of the costimulatory molecules CD80 and CD86 was not modulated by POM-1 (data not shown). In parallel, we observed a decrease of PD-L1 expression on LPS-stimulated M-CSF-macrophages or LPS-stimulated CD39^low M-CSF-macrophages upon treatment with POM-1 (Fig. 2D). By contrast, the expression of IL-12, both at the mRNA and protein levels, by all macrophage subsets, was not modulated by POM-1 (Fig. S3D and E and data not shown). These results suggest that CD39 plays a central role in regulating the expression of immunoregulatory molecules by M2-type macrophages, with a marginal effect if any on the expression of costimulatory molecules.

The addition of exogenous ATP slightly decreased IL-10 production but did not induce IL-12 production by M-CSF-macrophages and ovarian cancer-isolated TAM (data not shown) and did not affect IL-12 secretion by GM-CSF-macrophages (Fig. S3D). As a control, ATP significantly increased IL-1β secretion by LPS-activated M-CSF-macrophages (139.4 ± 58.3 pg/mL to 1070 ± 68.14 pg/mL in the absence or presence of ATP, respectively, mean ± SEM ; n = 4; p value = 0.005), TAM (from 111.4 ± 36.2 pg/mL to 239.6 ± 90.9 pg/mL; n = 3) and GM-CSF-macrophages (from 1557 ± 309.2 pg/mL to 8236 ± 3906 pg/mL; n = 4) (Fig. 2A and Fig. S3A). These data suggested that the hydrolysis of ATP may be pivotal in regulating the immunoregulatory phenotype of M-CSF-macrophages. As macrophages express adenosine receptors and that adenosine receptor stimulation regulates IL-10 secretion,⁵¹ we addressed the role of adenosine generated following ATP hydrolysis on the cellular fate of macrophages by using adenosine deaminase (ADA) that degrades adenosine, and caffeine that inhibits adenosine receptor. Results showed that inhibition of adenosine receptor during M-CSF-macrophages activation inhibits IL-10 secretion (Fig. S4). Likewise, the presence of ADA during the activation led to a similar decrease of IL-10 secretion by LPS-stimulated M-CSF-macrophages, ovarian cancer-isolated TAM (Fig. 2A) and GM-CSF-macrophages (Fig. S3A). Adenosine depletion showed no effect on IL-12 secretion by GM-CSF-macrophages (Fig. S3D) nor triggered IL-12 secretion by M-CSF-macrophages and ovarian cancer-isolated TAM (data not shown). Surprisingly, adenosine depletion triggered IL-1β secretion by M-CSF-macrophages and slightly increased IL-1β secretion by GM-CSF-macrophages upon stimulation with LPS (Fig. 2A, and Fig. S3A). The increase of IL-1β production was associated with an increase of IL-1β mRNA expression by both macrophage subsets (Fig. S3F).

Collectively, these results suggest that ATP metabolites, generated in a CD39-dependent manner, are involved in the acquisition of immunoregulatory properties by M-CSF-macrophages and ovarian cancer TAM.

The expression of CD39 is regulated by interleukin-27

Results underlined the pivotal role played by CD39 in controling the immunoregulatory properties of M-CSF-macrophages and ovarian cancer TAM. Previous studies have reported that IL-27 receptor knock-out down-modulates the expression of CD39 on dendritic cells and regulatory T cells.^52,53 LPS-stimulated human monocytes produce IL-27 (Fig. S5A) and LPS-stimulated macrophages expressed the transcript encoding IL-27, IL-27RA and gp130 (data not shown). We thus investigated the role of IL-27 in the CD39-mediated acquisition of an immunoregulatory phenotype by M-CSF-macrophages.

Neutralizing IL-27 during the 7-d culture of monocytes reduced membrane and mRNA CD39 expression by M-CSF-macrophages (Figs. 3A–B). Moreover, the neutralization of IL-27 decreased the ability of M-CSF-macrophages to produce IL-10 (Fig. 3C Left panel), to express IL-10 mRNA (Fig. 3C, right panel) and to express PD-L1 (Fig. 3D) in response to LPS. The modulation of PD-L1 expression by M-CSF-macrophages was comparable to one observed in the presence of POM-1 (18.1% decrease with anti-IL-27 Ab compared to 26.4% decrease with POM-1) (Figs. 2D and 3D) without affecting CD14 and CD163 expression (data not shown). These data suggest that autocrine IL-27 controls, at least in part, the acquisition of some immunoregulatory features by macrophage via the upregulation of CD39 expression.

Figure 3.

IL-27 blockade during macrophage differentiation in the presence of M-CSF-Mφ decreased CD39 expression. (A) M-CSF-Mφ was cultivated during 7 d with M-CSF in the presence of control medium, an anti-IL-27 antibody (5 µg/mL) or its control antibody. CD39 expression was analyzed by flow cytometry. Results are expressed in percent of CD39 expression in monocytes differentiated during 7 d with M-CSF as mean ± SEM (n = 4). (B) CD39 mRNA expression was analyzed by RT-qPCR. Results are expressed in mRNA expression normalized to GAPDH, as mean ± SEM (n = 4). (C, left panel) After stimulation of all type of macrophages generated with LPS (200 ng/mL) during 24 h, the secretion of IL-10 was analyzed by ELISA. Results are expressed in ng/mL as mean ± SEM (n = 5). (C, right panel) IL-10 mRNA expression was analyzed by RT-qPCR. Results are expressed in mRNA expression normalized to GAPDH, as mean ± SEM (n = 4). (D) All type of macrophages generated were stimulated with LPS (200 ng/mL) during 24 h. Expression of PD-L1 by M-CSF-Mφ was analyzed by flow cytometry. Results are expressed in percentage of RFI compared to LPS-stimulated M-CSF-Mφ as 100% (n = 5). *p < 0 .05 compared to differentiation process with control antibody or medium alone.

We thus evaluated IL-27 expression in ovarian cancer tissues. IHC revealed that infiltrating neutrophils are the main IL-27-producing cells in the tumors (Fig. 4A, middle and right panels). Interestingly, infiltrating CD163⁺ macrophages are in close vicinity of infiltrating neutrophils (Fig. 4A, middle and right panels). Only few IL-27-producing cells were detected in ovarian tissues from healthy subjects (Fig. 4A, left panel). In agreement with previous studies, we observed that peripheral blood neutrophils from healthy subjects constitutively express IL-27 (Fig. S5B). These data indicate that tumor-infiltrating neutrophils represent the major source of IL-27 in ovarian cancer tissue.

Figure 4.

IL-27 is expressed by tumor-infiltrating neutrophils in vicinity of CD163+ macrophages. Immunochemical analysis of IL-27 (A) and CD163 (B) in normal tissue (left panel) and in ovarian adenocarcinomas (right panels).

Discussion

In the present work, we report that the ectonucleotidase CD39, overexpressed by ovarian cancer TAM and by M-CSF-macrophages, is involved in the acquisition of some immunoregulatory features by these immunoregulatory cells. Moreover, we observed that, during the in vitro differentiation of monocytes into macrophages, the level of CD39 expression was controlled by autocrine IL-27. In spite of uprising their level of activation, CD39 blockade shifts human macrophages from an immunosuppressive toward a more inflammatory phenotype; however contrary to murine macrophages,⁵⁴ they remain unable to produce IL-12.

Even though human macrophages express low levels of membrane CD73,^47,55 we confirmed that macrophages express CD73 mRNA and that its expression is increased upon LPS stimulation. In line with this result we showed that (i) CD73 metabolites were diluted in the cell culture supernatant of macrophages and (ii) that CD73 inhibition prevents the production of Il-10 by activated macrophages (personal unpublished data). We thus focused this study on CD39 rather than on CD73 ³¹ or adenosine receptor blockade.²⁰ Indeed, blocking CD39 maintains a pool of extracellular ATP suitable for inflammasome activation and prevents the production of immunomodulatory adenosine. The capacity of TLR agonists to induce ATP release and to activate caspase-1, an activated cascade required to induce the release of active IL-1β by myeloid cells, has for long been subjected to controversy.^15,56 After stimulation with LPS alone, GM-CSF-macrophages but not M-CSF-macrophage produced IL-1β. This result suggested that GM-CSF-macrophages release their endogenous ATP after LPS activation, a result in agreement with Riteau et al. and Lévesque et al.^57,58 In the present study, the blockade of CD39 and the depletion of adenosine rendered human TAM and M-CSF-macrophages able to secrete IL-1β, a process that reflects their ability to release ATP. These results confirmed the importance of endogenous ATP for the tuning of immunostimulatory properties by human macrophages.

Extracellular nucleotides also regulate the fate of immune cells,^14,35 and immunosuppressive properties of adenosine in solid carcinomas have been extensively described.²⁰ Moreover, hypoxia modulates immune cell sensitivity to adenosine via increase of HIF1a expression which leads to modulation of CD73 and ADORA2A. Hypoxia has emerged as a major inducer of tumor immune suppression. Interestingly, studies have reported that Ado is involved in maintaining T cell immune suppression in hypoxic conditions. Based on these data, we could hypothesize that hypoxia may also participate/amplify the macrophage-dependent tumor-induced immune suppression induced by ATP metabolites.^31,36

CD39 belongs to the arsenal of regulatory T cells and ovarian cancer cells to generate an immunosuppressive environment.^43,46,59 Here, we describe that ovarian tumor-infiltrating macrophages are also active players of this process. Newly recruited monocytes in the tumor are in contact with ATP-derived nucleotides which may participate to the acquisition of an IL-10^high IL-12^low immunosuppressive phenotype.^10,60 As CD39 is located upstream the ATP metabolism, we hypothesized that manipulating the ATP/AMP ratio may modulate the immunosuppressive properties of M-CSF-macrophages. Accordingly, we observed that CD39 inhibition or adenosine depletion enhanced the capacity of activated TAM and M-CSF-macrophages to produce IL-1β and reduced their capacity to produce IL-10. The field of cancer immunology has recently been fed with studies on the roles of the ectonucleotidases CD39 and CD73 on the biology of tumor-associated immune cells, showing that CD39 and/or adenosine receptors are major negative regulators of T cells, myeloid cells and cancer cells that could be targeted within the tumor microenvironment.^20,21,43 To support our choice to target CD39, it has been shown that CD73 (an ectonucleotidase hydrolyzing AMP into Adenosine) may be dispensable for M2-type macrophage polarization.⁶¹

Numerous studies have underlined the role of IL-27 in the generation of an immunoregulatory microenvironment in physiological and pathological settings. IL-27 limits tissue inflammation and autoimmunity in various settings ⁶² and IL-27 inhibits Th17 cells and promotes Treg cells differentiation in tumors and inflamed skin.^63,64 IL-27 also confers immunosuppressive properties to several immune cells. Although the anti-inflammatory role of IL-27 has been reported during the course of inflammation,^52,65 knowledge is limited about its role during the regulation of myeloid cell polarization and in the regulation of innate immunity. IHC analysis of ovarian cancer tissues revealed that tumor-infiltrating neutrophils represent the main source of IL-27.

IL-27 potentiates immunosuppression at least by inducing the acquisition of CD39 at the surface on cells present in the tumor microenvironment.^43,59 However, this effect might depend on the target cells and on the microenvironment.⁶⁶ IL-27 polymorphisms affecting IL-27 have been associated to an increased susceptibility to ovarian cancer.⁶⁷ As proposed by Kalliolas et al.,⁶⁶ IL-27 may exhibit opposite effects on innate and adaptive immune cells. It is more likely that monocytes/macrophages express IL-27 upon stimulation. These results support the hypothesis that IL-27 might exert, at least, its immunosuppressor properties by increasing CD39 expression on TAM. As a matter of fact, IL-27 acts as a rheostat for CD39.

PD-L1 appears as an important immune checkpoint. Modulation of PD-L1 expression may impact the fate of tumor cells and infiltrating immune cells from the microenvironment in adenocarcinomas.^68-71 After CD39 blockade or IL-27 depletion, the reduced PD-L1 expression by macrophages might affect the ratio of costimulatory vs. coinhibitory molecules in the context of inflammation.

Ovarian cancer is the gynecological malignancy with the worse prognosis. TAM density was originally correlated with bad prognosis. Currently, different approaches have been proposed to avoid TAM polarization or to neutralize some immunosuppressive or pro-tumor factors produced by TAM (e.g. IL-10, VEGF, MMPs, IDO).⁶⁰ For this concern, to identify strategies that may inhibit their recruitment, block their generation, reverse their trophic and immunosuppressive roles or interfere with their survival may represent new therapeutic opportunities.¹⁰ As a matter of fact, our study identifying the role of membrane CD39 in the acquisition and maintenance of an immunosuppressive phenotype by M-CSF-macrophages and TAM, could define ATP metabolism and IL-27 as privileged targets.^54,55

Experimental procedures / materials and methods

Cell isolation and macrophage generation

Peripheral blood mononuclear cells (PBMC) were obtained from healthy human volunteers (Blood collection center, Angers, France; agreement ANG-2003-2). Ascites were collected from ovarian cancer patients with written informed consent in accordance with the Angers University Hospital ethics committee requirements and the declaration of Helsinki (Agreement 2013/38) and through the Center de Ressources Biologiques (CRB) Santé of Rennes (Agreement BB-0033-00056).

Mononuclear cells were isolated using standard Lymphocyte Separation Medium (PAA Laboratories, Pashing, Austria). CD14⁺ monocytes and CD14⁺ TAM were isolated by magnetic sorting (Miltenyi Biotec, Bergisch Gladbach, Germany). M-CSF-macrophages and GM-CSF-macrophages were generated by culturing monocytes (1 × 10⁶ cells/mL) for 7 d in RPMI 1640 medium supplemented with 10% fetal calf serum and antibiotics (all from Lonza, Verviers, Belgium) in the presence of 50 ng/mL M-CSF (ORF Genetics Kopavogur, Iceland) or 20 ng/mL GM-CSF (Cellgenix, Freiburg, Germany), respectively. In some experiments, in order to evaluate the role of IL-27 during the 7-d differentiation process, cells were cultured in the presence of 2.5 or 5 µg/mL anti-IL-27 (R&D Systems, Abingdon, UK) or isotype control Abs (Sigma-Aldrich, Saint-Louis, MO).

Neutrophils were isolated from blood by 3% dextran (Amersham Biosciences) density-gradient sedimentation. Contaminating red blood cells were lysed by hypo-osmotic shock. Purity was determined by FACS analysis on forward scatter/side scatter parameters; purity was routinely >96 %.

Cell activation

Macrophages were activated or not for 6 h or 24 h with 200 ng/mL LPS (from E. coli serotype O111:B4; Sigma-Aldrich). In some experiments, macrophages were cultured for 6 h or 24 h in the presence of 10 µM POM-1 (Tocris, Bristol, UK), a potent CD39 antagonist,⁵² or for 24 h in the presence of 0.25 UI/mL ADA (Sigma-Aldrich) containing less than 11 ng/mL endotoxin or Caffeine (Sigma-Aldrich), a pan adenosine receptor antagonist during activation with LPS.

Cytokine quantification

IL-1β, IL-10, IL-12 (Diaclone, Dijon, France) and IL-27 (R&D Systems) were quantified with ELISA.

Flow cytometry analysis

Cells were incubated with FITC-labeled anti-CD80, PE-labeled anti-CD86, PE-labeled anti-CD39 (all from BD PharMingen, San Diego, CA), BV421-labeled anti-PD-L1 (Biolegend, San Diego, CA), FITC-labeled anti-CD14 (Milteny biotec) or APC-labeled anti-CD163 (R&D Systems) mAbs. Data were acquired using a FACS Canto flow cytometer (BD Biosciences, San Jose, CA) and analyzed with the FlowJo software (Tree Star, Ashland, OR). Results are expressed as relative fluorescence intensities (RFI) determined as follows: (A/B), where A and B were the MFI values obtained with specific and isotype control mAbs, respectively. MFI values were determined on 7-AAD⁻ viable cells.

Analysis of mRNA expression

After cell lysis using the Trizol reagent (Life technologies, Saint-Aubin, France), total RNA were extracted using RNeasy Micro kit according to the manufacturer recommendations (Qiagen, Hilden, Germany) and reverse transcribed using Superscript II reverse transcriptase (Life technologies). The expression of IL-1β, IL-10, IL-12p35, IL-12p40, IL-27p28, CD39 and CD163 mRNA was analyzed by qPCR using the iQ™ SYBR® Green Supermix (Biorad, Marnes-la-Coquette, France); primer sequences are available upon request. Specific gene expression was calculated using the 2^−ΔΔCT method using GAPDH as calibrator.

HPLC measurements

Nucleotidase activity of in vitro generated M-CSF-Mϕ and GM-CSF-Mφ was assessed by measuring fluorescent etheno-ATP hydrolysis. Etheno-ATP was obtained by incubating ATP (100 mM) for 30 min at 72°C in the presence of 1 M chloroacetaldehyde and 25 mM Na₂HPO₄ (pH 4.0), as previously described.⁷² M-CSF-Mϕ and GM-CSF-Mϕ (500 × 10³ cells) were incubated at 37°C with 200 µM etheno-ATP, in the presence of 10 µM POM-1. At different time points (0, 10, 20, 50 min), a fraction of the supernatant was collected and precipitated on ice with 10% trichloroacetic acid (TCA; Sigma-Aldrich). Etheno-ATP, -ADP, -AMP and -Adenosine were separated by HPLC Waters purification systems (Alliance analytical, Fremont, CA) and C18 column (Sigma-Aldrich). Areas under the curve corresponding to each etheno nucleotide and etheno adenosine were integrated. Results were expressed as a percentage of each nucleotide present in the supernatants at the different time points, taking 100% as the dose of Etheno-ATP added at the start of the experiment and remaining without cells.

Immunohistochemistry (IHC)

Paraffin-embedded ovary biopsies from patients with ovarian adenocarcinomas or from healthy subjects were from the Department of Tissue Pathology of the University Hospital of Angers. After deparaffinization following Bond Max protocol (Leica) slides were treated with citrate for 30 min for IL-27-CD39-CD14 staining and with EDTA for 20 min for CD163 staining. IHC was performed using rabbit anti-human IL-27 (Abcam, Paris France), rabbit anti-human CD163 (Interchim, Montluçon, France), rabbit anti-human CD39 (Atlas antibodies) or mouse anti CD14 (Abcam) antibodies. Bound antibodies were detected with the HRP substrate 3, 3′-diaminobenzidine (brown) or Red Permanent (Red) After counter-staining with hematoxylin coloration, sections were mounted on coverslips and analyzed under a light microscope or NanoZoomer (Hamamatsu Photonics, Hamamatsu, Japan).

Immunofluorescence analysis

PNN were seeded on poly-L-lysine (Sigma-Aldrich) coated sterile at 1 × 10⁶ cells per mL in complete medium SVF 2%. Membrane Fc receptors were blocked with Human Immunoglobulin (IgH, Sigma-Aldrich). Cells were incubated with mouse anti-human CD66b PE or its control isotype for 15 min. and fixed with PFA 4% for 15 min. at room temperature. Cell permeabilization was obtained after 30 min. with PBS 0,1% saponin plus 2% BSA. Cells were incubated with goat anti-human anti-IL-27 (R&D) or its control isotype for 30 min. Cells were then incubated with anti-goat FITC for 30 min. Samples were mounted with proLong gold (Thermo Fischer Scientific) and analyzed with Leica TCS SP8 confocal microscope.

Statistical analysis

Statistical analyses were performed using GraphPad Prism 5 (GraphPad Software Inc., La Jolla, CA). Data are shown as mean ± SEM and were analyzed by Mann-Whitney test to analyze non-parametric data or one-way analysis of variance (ANOVA) with a post-hoc Bonferroni’s multiple comparison tests. Statistical significance was considered when p values were less than 0.05.

Disclosure of potential conflicts of interest

No potential conflicts of interest were disclosed.

Acknowledgments

The authors thank Dimitri Breard and David Macherel for HPLC experiments. The authors also thank members of the cellular and molecular facility (PACeM) of the University of Angers and members of the Cellular and Tissular Imaging core facility (MicroPICell) of the University of Nantes. The authors are grateful to Simon Blanchard, Isabelle Fremaux and Laurence Preisser for expert technical assistance.

Author contributions

Conceived and designed the experiments: SMDA, PJ, MG, YD, JT. Performed the experiments: SMDA, GK, CR, LB, LP. Analyzed the data: SMDA, GK, CR, LB, DH, AC, PJ, MG, YD, JT. Contributed reagents/materials/analysis tools: VC, NI, PD, AC. Wrote the paper: SMDA, PJ, MG, YD, JT.

Funding

This work was supported by institutional grants from INSERM and the University of Angers, and by a grant from the regional council Pays de la Loire (IMBIO-DC program) a grant from the Ligue contre le Cancer (Comité Départemental du Maine-et-Loire), and a grant from the Institut Recherche en Santé Respiratoire des Pays de la Loire. SMDA received a financial support from the regional council Pays de la Loire (IMBIO-DC program).